secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001367644-26-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EBS Q4 net loss $1.04/sh, FY2025 net income $0.93/sh; FY2026 rev guidance $720-760M
--------------------------------------------------------------------------------

- Full year 2025 total revenues $742.9M, down 29% from $1,043.6M in 2024.
- Q4 2025 net loss $54.6M ($1.04 loss per diluted share), vs Q4 2024 loss $31.3M.
- Full year 2025 net income $52.6M ($0.93 diluted EPS), vs prior year net loss $190.6M.
- Adjusted EBITDA for FY2025 $205.0M, up 12% from $183.1M in 2024.
- FY2026 guidance: revenues $720-760M, adjusted net income $25-45M, adjusted EBITDA $135-155M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/0001367644-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/ebs-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001367644-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer